Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Telmisartan/Amlodipine/HCTZ FDC vs Telmisartan/HCTZ + Amlodipine
NCT02129192Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, amlodipine and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Measured Concentration at 144 hours and Area Under the Concentration-time Curve from 0 to last quantifiable concentration at 144 hours. Started May 2014; status: completed.
02
Drugs
telmisartanamlodipinehydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02129192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129192.